[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112016018224A2 - conjugados de fviii - Google Patents

conjugados de fviii

Info

Publication number
BR112016018224A2
BR112016018224A2 BR112016018224A BR112016018224A BR112016018224A2 BR 112016018224 A2 BR112016018224 A2 BR 112016018224A2 BR 112016018224 A BR112016018224 A BR 112016018224A BR 112016018224 A BR112016018224 A BR 112016018224A BR 112016018224 A2 BR112016018224 A2 BR 112016018224A2
Authority
BR
Brazil
Prior art keywords
conjugates
fviii conjugates
fviii
heparosane
hemophilia
Prior art date
Application number
BR112016018224A
Other languages
English (en)
Inventor
Behrens Carsten
Michael Haller Friedrich
Deangelis Paul
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR112016018224A2 publication Critical patent/BR112016018224A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção refere-se ao fviii conjugado aos polímeros de heparosano (hep), métodos para a fabricação dos mesmos e usos de tais conjugados. os conjugados resultantes podem ser usados no tratamento ou prevenção de distúrbios de sangramento tal como hemofilia.
BR112016018224A 2014-02-12 2015-02-12 conjugados de fviii BR112016018224A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14154876 2014-02-12
PCT/EP2015/053025 WO2015121382A1 (en) 2014-02-12 2015-02-12 Factor viii conjugates

Publications (1)

Publication Number Publication Date
BR112016018224A2 true BR112016018224A2 (pt) 2017-10-17

Family

ID=50071544

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016018224A BR112016018224A2 (pt) 2014-02-12 2015-02-12 conjugados de fviii

Country Status (14)

Country Link
US (2) US20150224203A1 (pt)
EP (1) EP3104893A1 (pt)
JP (1) JP2017507135A (pt)
KR (1) KR20160120296A (pt)
CN (1) CN105979972A (pt)
AR (1) AR101060A1 (pt)
AU (1) AU2015216985A1 (pt)
BR (1) BR112016018224A2 (pt)
CA (1) CA2939441A1 (pt)
IL (1) IL246713A0 (pt)
MX (1) MX2016010231A (pt)
RU (1) RU2016134357A (pt)
TW (1) TW201613650A (pt)
WO (1) WO2015121382A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR099340A1 (es) * 2014-02-12 2016-07-13 Novo Nordisk As Conjugados del factor de coagulación ix
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
AU2019366942A1 (en) * 2018-10-23 2021-06-10 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor VIII function
KR101964405B1 (ko) 2018-12-17 2019-04-01 영동이앤지(주) 교량 받침의 연단거리 측정점검 장치

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7211558B2 (en) * 2002-05-22 2007-05-01 The Children's Hospital Of Philadelphia Compositions and methods for the treatment of hemophilia A
WO2007056191A2 (en) * 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
MX2010009154A (es) * 2008-02-27 2010-09-09 Novo Nordisk As Moleculas conjugadas del factor viii.
US9687559B2 (en) * 2008-03-19 2017-06-27 The Board Of Regents Of The University Of Oklahoma Heparosan polymers and methods of making and using same for the enhancement of therapeutics
EP2341941A4 (en) * 2008-09-09 2014-12-10 Univ Oklahoma HEPAROSANE POLYMERS AND METHODS OF MAKING AND USING THEM TO ENHANCE THERAPEUTIC COMPOUNDS
US20130040888A1 (en) * 2010-02-16 2013-02-14 Novo Nordisk A/S Factor VIII Molecules With Reduced VWF Binding
CN104411323A (zh) * 2012-04-24 2015-03-11 诺和诺德A/S（股份有限公司） 适用于治疗血友病的药物组合物
JP2015515482A (ja) * 2012-04-24 2015-05-28 ノヴォ ノルディスク アー／エス 血友病の治療に適する化合物
EP2970933A2 (en) * 2013-03-12 2016-01-20 Novo Nordisk A/S Thrombin sensitive coagulation factor x molecules
MX2016004702A (es) * 2013-10-15 2016-07-22 Novo Nordisk Healthcare Ag Polipeptidos del factor vii de coagulacion.

Also Published As

Publication number Publication date
RU2016134357A (ru) 2018-03-16
AU2015216985A1 (en) 2016-07-28
AR101060A1 (es) 2016-11-23
JP2017507135A (ja) 2017-03-16
KR20160120296A (ko) 2016-10-17
CN105979972A (zh) 2016-09-28
EP3104893A1 (en) 2016-12-21
WO2015121382A1 (en) 2015-08-20
US20150224203A1 (en) 2015-08-13
US20160120953A1 (en) 2016-05-05
IL246713A0 (en) 2016-08-31
TW201613650A (en) 2016-04-16
MX2016010231A (es) 2016-10-13
CA2939441A1 (en) 2015-08-20

Similar Documents

Publication Publication Date Title
MX2021006581A (es) Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia.
BR112017006664A2 (pt) terapias de combinação
EA201890204A1 (ru) Антибактериальные соединения
BR112017023161A2 (pt) composições de ácido obeticólico e métodos de uso
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
MX2018007423A (es) Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas.
EA201890111A1 (ru) Замещенные производные оксопиридина
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
BR112018016433A2 (pt) inibidores de heteroarila de pad4
MX2017001281A (es) Material anisotropico biocompuesto, implantes medicos que lo comprenden y metodos para el tratamiento del mismo.
BR112014021104A2 (pt) métodos e composições para o tratamento da doença de huntington
PH12016502015A1 (en) Anti-factor d antibody variants and uses thereof
BR112017003705A2 (pt) compostos contendo nitrogênio tricíclicos para o tratamento de infecção por neisseria gonorrhoea
MX2019006291A (es) Composiciones de lactato de calcio y metodos de uso.
BR112018011633A2 (pt) inibidores de aza-benzimidazol de pad4
BR112018011504A2 (pt) microcápsulas de trombina
BR112016018224A2 (pt) conjugados de fviii
BR112017024908A2 (pt) usos terapêuticos da 4-cloroquinurenina
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
PH12016502322A1 (en) Compounds and methods for preventing or treating malaria
MX2015012720A (es) Sales basicas de adicion de nitroxolina y usos de las mismas.
TW201713686A (en) Methods for preparing modified von Willebrand factor
BR112018076619A2 (pt) composições antimalariais e usos das mesmas
BR112017012794A2 (pt) copolímeros de polidialimina reticulados para o tratamento do diabetes do tipo 2
MX2016010229A (es) Conjugados del factor vii.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B15K Others concerning applications: alteration of classification

Ipc: A61K 47/00 (2006.01), A61P 7/02 (2006.01)

B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]